- Home
- TECX vs FLGT Comparison
TECX vs FLGT Comparison
Compare TECX & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- FLGT
- Stock Information
- Founded
- TECX 2019
- FLGT 2011
- Country
- TECX United States
- FLGT United States
- Employees
- TECX N/A
- FLGT N/A
- Industry
- TECX
- FLGT Medical Specialities
- Sector
- TECX
- FLGT Health Care
- Exchange
- TECX Nasdaq
- FLGT Nasdaq
- Market Cap
- TECX 647.7M
- FLGT 683.5M
- IPO Year
- TECX 2018
- FLGT 2016
- Fundamental
- Price
- TECX $47.44
- FLGT $18.34
- Analyst Decision
- TECX Strong Buy
- FLGT Hold
- Analyst Count
- TECX 5
- FLGT 1
- Target Price
- TECX $72.25
- FLGT $22.00
- AVG Volume (30 Days)
- TECX 93.8K
- FLGT 298.0K
- Earning Date
- TECX 11-07-2024
- FLGT 11-08-2024
- Dividend Yield
- TECX N/A
- FLGT N/A
- EPS Growth
- TECX N/A
- FLGT N/A
- EPS
- TECX N/A
- FLGT N/A
- Revenue
- TECX N/A
- FLGT $277,761,000.00
- Revenue This Year
- TECX N/A
- FLGT N/A
- Revenue Next Year
- TECX N/A
- FLGT $16.00
- P/E Ratio
- TECX N/A
- FLGT N/A
- Revenue Growth
- TECX N/A
- FLGT N/A
- 52 Week Low
- TECX $1.40
- FLGT $16.56
- 52 Week High
- TECX $53.34
- FLGT $30.68
- Technical
- Relative Strength Index (RSI)
- TECX 53.77
- FLGT 41.26
- Support Level
- TECX $42.83
- FLGT $19.25
- Resistance Level
- TECX $48.85
- FLGT $21.36
- Average True Range (ATR)
- TECX 3.42
- FLGT 0.88
- MACD
- TECX -0.84
- FLGT -0.11
- Stochastic Oscillator
- TECX 43.97
- FLGT 0.66
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.